Millipore Sigma Webinar

« Previous article
SphereFlash® AI ...

29th January 2024  Product update: rapidmicrobiology staff writer

DiaSorin Submits LIAISON® LymeDetect® Test for FDA Approval

LIAISON® LymeDetect® is a novel test with breakthrough potential that uses 3 chemiluminescent immunoassays for the early diagnosis of Lyme disease. It detects, in conjunction with clinical signs and symptoms, early Borrelia burgdorferi infections in human subjects.

The test, developed in partnership with QIAGEN allows the detection of IgG, IgM and T-cell mediated response, which can be measured through the QIAGEN’s proprietary QuantiFERON® technology, an interferon-gamma release assay (IGRA).

The development of LIAISON® LymeDetect® is part of the global partnership with QIAGEN, which also includes the LIAISON® QuantiFERON®-TB Gold Plus Test, for fast and accurate detection of latent tubercolosis infections.


Share on:


Date Published: 29th January 2024

Source article link: View

Note: This content has been edited by a rapidmicrobiology staff writer for style and content.

View full company details

Fijifilm Pyrostar testing critical water used in the reprocessing of medical devices

SGL Plates and Culture Media for Pharmaceutical Microbiology

AI for microbiology

QC Standards Controls and Proficiency Testing Schemes

Get our eNewsletter
Over 7,000 microbiology professionals get our weekly eNewsletter - subscribe now and find out why!